Table 2. Effectiveness of the perindopril shown for the whole study cohort. * significant difference from previous visit, p < 0.001 .
| Baseline (n=1255) |
Visit 1 (3 months from the baseline) (n=1249) |
Visit 2 (6 months from the baseline) (n=1229) |
Visit 3 (9 months from the baseline) (n=1194) |
Δbaseline-Visit 3 | |
|---|---|---|---|---|---|
| Systolic blood pressure (mmHg) | 159.9±13.8 | 144.5±23.2* | 135.9±10.9* | 131.7±9.0* | 28.2±14.0* |
| Diastolic blood pressure (mmHg) | 96.4±21.3 | 86.9±8.1* | 83.0±24.4* | 79.9±7.3* | 16.8±22.3* |
| Percent of patients achieving systolic normotension (<140 mmHg) | 0% | 339 (27.1%) | 697 (56.7%) | 910 (76.6%) | 76.6% |
| Percent of patients achieving diastolic normotension (<90 mmHg) | 0% | 618 (49.5%) | 946 (77.0%) | 1075 (90.5%) | 90.5% |
| Percent of patients achieving both systolic and diastolic normotension (<140/90 mmHg) | 0% | 282 (22.6%) | 646 (52.6%) | 873 (73.5%) | 73.5% |
| Percent of patients with reduction of systolic pressure ≥10 mmHg | 0% | 1005 (80.5%) | 1140 (92.8%) | 1144 (96.3%) | 96.3% |
| Percent of patients with reduction of diastolic pressure ≥5 mmHg | 0% | 969 (77.6%) | 1105 (89.9%) | 1121 (96.4%) | 96.4% |